Drug Profile
PRO 131921
Alternative Names: PRO-131921Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Genentech
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; B cell inhibitors; CD20 antigen inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 08 Dec 2009 Safety, pharmacokinetics and efficacy data from a phase I/II trial in Non-Hodgkin's lymphoma were presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009)
- 19 Jun 2009 Discontinued - Phase-I/II for Non-Hodgkin's lymphoma in USA (IV)
- 01 Jun 2009 Discontinued - Phase-I/II for Chronic lymphocytic leukaemia in USA (IV)